The Global Polymerase Chain Reaction Market to Surpass USD

New York, USA, Oct. 05, 2022 (GLOBE NEWSWIRE) — The Global Polymerase Chain Reaction Market to Surpass USD 8 Billion Mark by 2027 | DelveInsight

The polymerase chain reaction market is expected to grow in revenue due to factors such as an increase in the prevalence of pathogen-caused diseases, increasing applications in the field of clinical diagnostics, and latest technological advancements to improve its accuracy further. 

DelveInsight’s Polymerase Chain Reaction Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, polymerase chain reaction market drivers, barriers, and trends, and key polymerase chain reaction companies in the market. 

Key Takeaways from the Polymerase Chain Reaction Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global polymerase chain reaction market during the forecast period. 
• Notable polymerase chain reaction companies such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Qiagen, Agilent Technologies Inc., Standard Biotools, F. Hoffmann-La Roche Ltd., Eppendorf, Avance Biosciences Inc., Merck & Co. Inc., Abbott, Promega Corporation, Takara Bio Inc., Endress+Hauser Group Services AG, BioMérieux, GenMark Diagnostics Inc., Grifols SA, Hologic Inc., BD, Sysmex Corporation, Stilla, and several others are currently operating in the polymerase chain reaction market.
• In January 2022, Qiagen collaborated with  for the use of QIAcuity digital PCR instruments. Atila Biosystems will provide non-invasive prenatal testing, and Actome extends QIAcuity reach from genomics to prAtila Biosystems and Actome GmbHoteomics.
• In June 2021, Bio-Rad collaborated with Seegene Inc. to produce molecular diagnostic products related to infectious diseases. Through this, Seegene shall provide diagnostic tests in U.S markets for use on Bio-Rad’s LFX960x real-time PCR system.
• In March 2021, MatMa…